4D Molecular Therapeutics (FDMT) Retained Earnings (2019 - 2026)

4D Molecular Therapeutics (FDMT) has reported Retained Earnings for 7 consecutive years, with -$785.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Retained Earnings fell 25.78% year-over-year to -$785.1 million; the TTM figure through Mar 2026 stood at -$785.1 million (down 25.78% YoY), while the FY2025 annual figure was -$716.3 million, down 24.32% from the prior year.
• Retained Earnings eased to -$785.1 million in Q1 2026 per FDMT's latest filing, from -$716.3 million in the prior quarter.
• Across five years, Retained Earnings topped out at $534000.0 in Q3 2023 and bottomed at -$785.1 million in Q1 2026.
• Historically, Retained Earnings has averaged -$372.4 million across 5 years, with a median of -$372.8 million in 2023.
• Annual changes were most pronounced in 2023 — Retained Earnings surged 100.19% — and 2025, when it tumbled 572560.55%.
• 4D Molecular Therapeutics' Retained Earnings stood at -$314.5 million in 2022, then plunged by 32.06% to -$415.3 million in 2023, then sank by 38.73% to -$576.2 million in 2024, then declined by 24.32% to -$716.3 million in 2025, then retreated by 9.6% to -$785.1 million in 2026.
• Business Quant data shows FDMT's Retained Earnings at -$785.1 million in Q1 2026, -$716.3 million in Q4 2025, and -$735.7 million in Q3 2025.